Skip to main content
OpenTrials
Completed

NCT Number: NCT01375881

Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice

The purpose of this non-interventional study is a description of use of darunavir in daily practice, in retrospective and perspective manner. Darunavir will be prescribed in the usual manner and in accordance with the terms of marketing authorization. The assignment of a patient to a particular therapeutic strategy will not be decided in advance by this study protocol but instead, it will be part of the current clinical practice. The prescription of the medicinal product will be clearly separated from the decision to include the patient in the study. No additional diagnostic or monitoring procedures will be applied to the patients, and epidemiological methods will be used for the analysis of collected data. After having agreed with the patient on starting treatment with darunavir, and provided that all inclusion and exclusion criteria apply, the physician will document the patient's data. Patients will be observed for at least 48 weeks from baseline visit except for those who withdraw from the study earlier. Patients data will be collected at approximately 0, 1, 3 and 6 months after starting treatment and subsequently every 3 months in accordance with routine practice. The expected number of patients to enroll is about 900. The patients will be treated with darunavir according to the Italian label. The patient must be withdrawn from the study if the treatment with darunavir has been stopped. A last evaluation must be documented when possible, and a resistance test will be collected if available for patients discontinuing for virologic failure. At the end of study visit, information on therapy given after darunavir discontinuation will be collected. For patients discontinuing for virologic failure, data will be collected until the end of the present study, and at least two consecutive measurements of viral load after starting new antiretroviral therapy will be collected, if available. All data collected must be the result of the normal medical care of the patient. The patient's baseline data will be collected within the first week before darunavir administration (at Visit 1). For patients already in treatment with darunavir, baseline and follow up data will be collected retrospectively and prospectively. Further data collection will occur approximately at 1, 3, and 6 months and subsequently about every 3 months according to routine practice, after initiating darunavir treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Infections Blood-Borne Infections Communicable Diseases Genital Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The patient's baseline data will be collected within the first week before darunavir administration, Visit 1. For patients already in treatment with darunavir, outside the Early Access Program, baseline and follow-up data will be collected retrospectively and prospectively. For patients switched to commercial darunavir from the Early Access Program and already in treatment with darunavir, Baseline Visit data will be collected from the Early Access Program Baseline Visit. For patients already in treatment with darunavir outside the Early Access Program, baseline data will be collected retrospectively starting from the first darunavir intake. For all patients, laboratory examination results collected within 6 months before darunavir treatment starts will be considered as baseline data. For patients switched to commercial darunavir from the Early Access Program and already in treatment with darunavir, Visit 2 won't be performed. For patients starting commercial darunavir or already in treatment with commercial darunavir outside the Early Access Program, laboratory exams related to follow-up visits, Visit 2 onward, can be performed within a time window of one month before or after the corresponding visit date. Further data collection will occur approximately at 1, 3, and 6 months and subsequently about every 3 months according to routine practice, after initiating darunavir treatment. If a patient stops treatment with darunavir at any time, the end of study visit should be performed as soon as possible. Darunavir film-coated tablet, orally administered. Orange, oval-shaped tablet, debossed with 400MG or 600MG or 300MG on one side and TMC on the other side. Duration of observation minimum 48 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eligible for inclusion in this non-interventional study are adult patients in need of treatment with darunavir according to Italian label or already in treatment
  • Having provided a signed and dated Informed Consent Form

Exclusion criteria

  • A known hypersensitivity to darunavir or to any of its excipients
  • Severe hepatic impairment described as Child-Pugh class C
  • Pregnancy or lactation
  • Patient previously treated with darunavir that was discontinued for any reason

Treatment and study plan

darunavir/ritonavir plus background regimen

Drug

darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages

Primary outcomes

  1. Measurement of viral load, as an assessment of efficacy

    Time frame: At least 48 weeks

Secondary outcomes

  1. Immunological response, as measured by CD4 cells count

    Time frame: At least 48 weeks

  2. Impact on Health-related Quality of Life after switching to a darunavir containing regimen in accordance to the approved indication

    Time frame: At least 48 weeks

  3. Neuropsychological impairment at baseline and after switching to a darunavir containing regimen in accordance to the approved indication

    Time frame: At least 48 weeks

  4. Assessments of non-categorized information gathered about treatment switch to and from darunavir

    Time frame: At least 48 weeks

  5. Number of patients with adverse events, as a measure of safety

    Time frame: At least 48 weeks

Sponsors and collaborators

Lead sponsor

Janssen-Cilag S.p.A.

Industry

Registry information

Official study title

Post Authorization Non-interventional Study in HIV1-Infected Patients Starting or Already in Treatment With Darunavir

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Jun 17, 2011
Registry last updated
May 6, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.